Department of Ophthalmology, Eye and ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3575-82. doi: 10.1167/iovs.09-4373. Epub 2010 Feb 17.
PURPOSE. To evaluate the effects of intravitreal injection of liposomes encapsulating tacrolimus (FK506) on experimental autoimmune uveoretinitis (EAU) in Lewis rats. METHODS. Liposomes containing tacrolimus were prepared by reverse-phase evaporation vesicles. EAU was induced in Lewis rats by subcutaneous injection of interphotoreceptor retinoid-binding protein R16 peptide emulsified in adjuvant. Ten days later, rats were intravitreally injected with saline, tacrolimus, tacrolimus-loaded liposomes, or unloaded liposomes. Clinical signs of inflammation and ocular histologic sections were observed and graded. Retinal function was evaluated by electroretinography (ERG). Tacrolimus concentration was determined in the vitreous body and serum by ELISA. Ocular biodistribution of rhodamine-conjugated liposomes containing tacrolimus (tacrolimus-Rh-lip) was analyzed with a laser scanning confocal microscope. To evaluate the systemic effect of intravitreally injected tacrolimus, delayed-type hypersensitivity (DTH) and lymphocyte proliferation assay (LPA) responses were detected. RESULTS. Treatment of EAU with intravitreal injection of liposomal tacrolimus significantly reduced intraocular inflammation and markedly inhibited the development of EAU, as determined in clinical and histopathologic analyses. No toxic effects could be detected as evaluated by ERG. The concentration of tacrolimus in ocular fluids remained for as long as 14 days after liposomal injection of tacrolimus. Confocal microscopy showed a transretinal distribution of the liposomal particles. DTH and LPA responses were not impaired in liposomal tacrolimus-treated rats. CONCLUSIONS. Intravitreal injection of liposomal tacrolimus was highly effective in suppressing the process of EAU without any side effects on retinal function or systemic cellular immunity. This treatment may represent a new option for the management of intraocular inflammation.
目的。评估玻璃体内注射包载他克莫司(FK506)的脂质体对实验性自身免疫性葡萄膜炎(EAU)在 Lewis 大鼠中的作用。
方法。通过反相蒸发法制备包载他克莫司的脂质体。通过在佐剂中乳化的感光细胞间视黄醇结合蛋白 R16 肽对 Lewis 大鼠进行皮下注射,诱导 EAU。10 天后,大鼠玻璃体内注射生理盐水、他克莫司、载他克莫司脂质体或未载药脂质体。观察和分级评估炎症的临床体征和眼部组织学切片。通过视网膜电图(ERG)评估视网膜功能。通过 ELISA 测定玻璃体内和血清中的他克莫司浓度。用激光扫描共聚焦显微镜分析含他克莫司的罗丹明标记脂质体(他克莫司-Rh-脂质体)的眼内分布。为了评估玻璃体内注射他克莫司的全身作用,检测迟发型超敏反应(DTH)和淋巴细胞增殖试验(LPA)反应。
结果。玻璃体内注射脂质体他克莫司治疗 EAU 可显著减轻眼内炎症,并明显抑制 EAU 的发展,这可通过临床和组织病理学分析来确定。通过 ERG 评估未发现任何毒性作用。脂质体注射他克莫司后,眼部液中的他克莫司浓度可维持长达 14 天。共聚焦显微镜显示脂质体颗粒经视网膜分布。脂质体他克莫司治疗大鼠的 DTH 和 LPA 反应未受损。
结论。玻璃体内注射脂质体他克莫司对抑制 EAU 过程非常有效,且对视网膜功能或全身细胞免疫无任何副作用。这种治疗可能为眼内炎症的治疗提供新的选择。